AR123371A1 - GLYCOSYLATED IL-2 PROTEINS AND THEIR USES - Google Patents
GLYCOSYLATED IL-2 PROTEINS AND THEIR USESInfo
- Publication number
- AR123371A1 AR123371A1 ARP210102424A ARP210102424A AR123371A1 AR 123371 A1 AR123371 A1 AR 123371A1 AR P210102424 A ARP210102424 A AR P210102424A AR P210102424 A ARP210102424 A AR P210102424A AR 123371 A1 AR123371 A1 AR 123371A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- sequence identity
- tag2
- tag1
- ala
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una secuencia de proteína IL-2 de la fórmula (Tag¹)ʸ - (Ala)ˣ - SEQ A - SEQ B - SEQ C - (Tag²)ᶻ (I), en donde SEQ A tiene al menos 89% de identidad de secuencia con SEQ ID Nº 1; SEQ B tiene al menos 76% de identidad de secuencia con SEQ ID Nº 2 y comprende al menos un motivo de glicosilación; SEQ C tiene al menos 91% de identidad de secuencia con SEQ ID Nº 4; Tag¹ y Tag² son independientemente una porción tag; Ala es un residuo de alanina; x es 0 ó 1; y es 0 ó 1; y z es 0 ó 1; a conjugados de esta y sus usos en el tratamiento de trastornos de proliferación celular. Reivindicación 1: Una secuencia de proteína IL-2 caracterizada por la fórmula (I) (Tag¹)ʸ - (Ala)ˣ - SEQ A - SEQ B - SEQ C - (Tag²)ᶻ (I), en donde SEQ A tiene al menos 89% de identidad de secuencia con SEQ ID Nº 1; SEQ B tiene al menos 76% de identidad de secuencia con SEQ ID Nº 2 y comprende al menos un motivo de glicosilación; SEQ C tiene al menos 91% de identidad de secuencia con SEQ ID Nº 4; Tag¹ y Tag² son independientemente una porción tag; Ala es un residuo de alanina; x es 0 ó 1; y es 0 ó 1; y z es 0 ó 1. Reivindicación 14: Un conjugado caracterizado porque comprende una o más de las proteínas IL-2 de acuerdo con cualquiera de las reivindicaciones 1 a 13. Reivindicación 33: Una composición farmacéutica caracterizada porque comprende al menos una proteína IL-2 de acuerdo con cualquiera de las reivindicaciones 1 a 13 o al menos un conjugado o la sal aceptable desde el punto de vista farmacéutico de este de acuerdo con cualquiera de las reivindicaciones 14 a 32 y al menos un excipiente. Reivindicación 39: Un oligonucleótido caracterizado porque codifica la proteína IL-2 de acuerdo con la reivindicación 1.An IL-2 protein sequence of the formula (Tag¹)ʸ - (Ala)ˣ - SEQ A - SEQ B - SEQ C - (Tag²)ᶻ (I), wherein SEQ A has at least 89% sequence identity with SEQ ID No. 1; SEQ B has at least 76% sequence identity to SEQ ID NO: 2 and comprises at least one glycosylation motif; SEQ C has at least 91% sequence identity with SEQ ID NO: 4; Tag¹ and Tag² are independently a tag portion; Ala is an alanine residue; x is 0 or 1; y is 0 or 1; and z is 0 or 1; to conjugates thereof and their uses in the treatment of cell proliferative disorders. Claim 1: An IL-2 protein sequence characterized by the formula (I) (Tag¹)ʸ - (Ala)ˣ - SEQ A - SEQ B - SEQ C - (Tag²)ᶻ (I), wherein SEQ A has at minus 89% sequence identity to SEQ ID NO: 1; SEQ B has at least 76% sequence identity to SEQ ID NO: 2 and comprises at least one glycosylation motif; SEQ C has at least 91% sequence identity with SEQ ID NO: 4; Tag¹ and Tag² are independently a tag portion; Ala is an alanine residue; x is 0 or 1; y is 0 or 1; and z is 0 or 1. Claim 14: A conjugate characterized in that it comprises one or more of the IL-2 proteins according to any of claims 1 to 13. Claim 33: A pharmaceutical composition characterized in that it comprises at least one IL-2 protein according to any of claims 1 to 13 or at least one conjugate or pharmaceutically acceptable salt thereof according to any of claims 14 to 32 and at least one excipient. Claim 39: An oligonucleotide characterized in that it encodes the IL-2 protein according to claim 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063071627P | 2020-08-28 | 2020-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123371A1 true AR123371A1 (en) | 2022-11-23 |
Family
ID=84578085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102424A AR123371A1 (en) | 2020-08-28 | 2021-08-27 | GLYCOSYLATED IL-2 PROTEINS AND THEIR USES |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116507633A (en) |
| AR (1) | AR123371A1 (en) |
-
2021
- 2021-08-27 AR ARP210102424A patent/AR123371A1/en unknown
- 2021-08-27 CN CN202180073386.7A patent/CN116507633A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116507633A (en) | 2023-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Döbeli et al. | Role of the carboxy-terminal sequence on the biological activity of human immune interferon (IFN-γ) | |
| US5650494A (en) | Process for refolding recombinantly produced TGF-β-like proteins | |
| US5486503A (en) | Anti-fungal histatin-based peptides | |
| UY23561A1 (en) | PROCEDURE FOR THE PREPARATION OF TNF-MUTEINS | |
| DE60125381D1 (en) | COMPOSITIONS AND METHODS FOR ANALOGUE OF G-CSF | |
| MX2023002047A (en) | Glycosylated il-2 proteins and uses thereof. | |
| AR123978A1 (en) | VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE | |
| PT87562A (en) | PROCEDURE FOR EXPRESSION OF PROAPOLIPOPROTEINE A-I HUMAINE | |
| AR047347A1 (en) | BACILLUS CRY9 FAMILY MEMBERS | |
| AR044024A1 (en) | MUTANT OF REPLACEMENT OF THE HUMAN IL-18, BIOLOGICALLY ACTIVE COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE SUCH COMPOSITION, METHOD TO PREPARE IT AND METHOD TO IMPROVE THE PHARMACOCINETICS AND PHARMACODYNAMICS OF THE ILL-18 HUMAN SUCH | |
| BRPI0519193A2 (en) | Method for producing sterile or lyophilized suspensions of poorly soluble basic peptide complexes, pharmaceutical formulations containing them, and application thereof as medicaments | |
| BRPI0109494B8 (en) | factor viii mutein, DNA sequence, vector, process for producing factor viii mutein, pharmaceutical composition and use of factor viii mutein | |
| BRPI0412799A (en) | immunogen, composition, nucleic acid, recombinant cell, methods for preparing a polypeptide, for inducing a protective immune response in a patient and for inducing an anamnesic response in a patient, and optimized yeast nucleic acid sequence | |
| CO2021017664A2 (en) | peptides | |
| BRPI0511005A (en) | oligomeric peptides and their use for the treatment of HIV infections | |
| HRP20110430T1 (en) | Fsh glycosylation mutant | |
| BR112022023288A2 (en) | ACTIVABABLE IL-12 POLYPEPTIDES AND METHODS OF USE THEREOF | |
| BR112022011975A2 (en) | MODIFIED INTERFERON-2 POLYPEPTIDE, MODIFIED GMOP-INTERFERON-2 POLYPEPTIDE, NUCLEIC ACID, PLASMID, VECTOR, CELL LINE, METHOD FOR PURIFICATION OF MODIFIED INTERFERON-2 POLYPEPTIDE, PHARMACEUTICAL COMPOSITION, METHOD FOR USE OF ONE OR MORE OF MODIFIED INTERFERON-¿2 POLYPEPTIDES AND METHOD TO TREAT A MEDICAL CONDITION IN AN INDIVIDUAL | |
| AR123371A1 (en) | GLYCOSYLATED IL-2 PROTEINS AND THEIR USES | |
| BR9700957A (en) | Mutant human growth hormone protein deoxyribonucleotide peptide of a protein expression plasmid antibody product medications for the treatment of gigantism and acromegaly and for gene therapy | |
| KR900702027A (en) | Derivatives of human / bovine basic fibroblast growth factor | |
| ATA3552000A (en) | XYLOSYL TRANSFERASE GENE | |
| BR112022026248A2 (en) | CYTOKINE CONJUGATES | |
| AU719526B2 (en) | New form of amphiregulin, methods for producing and using the same and compositions comprising the same | |
| DE68916850T2 (en) | Anticoagulant peptide alcohols. |